mn-166
mn-166: developed by 1 company · 3 clinical trials tracked.
mn-166 evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could mn-166 → MNOV affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| MEDICINOVA INC (MNOV) Amyotrophic Lateral Sclerosis; Glioblastoma | Phase 1/Phase 2 |
Clinical Trials (3)
Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS
A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis
Primary endpoint: Change from baseline in ALSFRS-R score at Month 12 (or last measurement before death in case of censoring) and survival time.
Phase 1b/2a Single-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of MN-166 (Ibudilast) and Temozolomide Combination Treatment in Patients With Newly Diagnosed or Recurrent Glioblastoma
Primary endpoint: Evaluate safety and tolerability of ibudilast and temozolomide combination treatment
Frequently asked questions
Who is developing mn-166?
mn-166 is being developed by MEDICINOVA INC.
How many clinical trials involve mn-166?
BioSniper tracks 3 clinical trials involving mn-166.